YM BioSciences to Present at RBC Healthcare Conference

MISSISSAUGA, Canada ? December 9, 2008 ? YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that David Allan, Chairman  and CEO of YM will be presenting as a panel participant at the 2008 RBC Capital Markets Healthcare Conference, held at the Westin Times Square Hotel in New York City. The panel titled Antibody Strategies For Fighting Cancer is scheduled from 3:30 pm to 4:25 pm (Eastern Time) on December 10, 2008 in Panel Room 2. Interested parties can access a live audio webcast of the panel by visiting YM?s website at www.ymbiosciences.com. The webcast will be available for 30 days after the conference.

 
About YM BioSciences

YM BioSciences Inc. is a company that identifies, develops and commercializes differentiated products principally in the area of oncology for patients worldwide.  The Company is developing nimotuzumab, a humanized monoclonal antibody, and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab is in development targeting multiple tumour types in combination with radiation, chemoradiation and chemotherapy. The drug, which is approved for marketing in a number of countries, is significantly differentiated from all other currently marketed EGFR-targeting agents because of a remarkably benign side-effect profile. In more than 3,000 patients treated worldwide, to date, no Grade III/IV rash or radiation dermatitis has been reported and reports of any of the other side-effects that are typical of EGFR-targeting molecules have been rare. AeroLEF® is in development for the treatment of moderate to severe pain, including cancer pain. The product completed a randomized trial in 2007 and is being prepared for late-stage development internationally.